Protagenic Therapeutics, Inc. (PTIX)

US — Healthcare Sector
Peers: SBHMY  ZIVO  CYT  ELDN    RZLT  XOMAO  TPST  AVTE  ADAG  ACRV  ANTX 

Automate Your Wheel Strategy on PTIX

With Tiblio's Option Bot, you can configure your own wheel strategy including PTIX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PTIX
  • Rev/Share 0.0
  • Book/Share -0.1688
  • PB -22.8132
  • Debt/Equity 0.0
  • CurrentRatio 0.8618
  • ROIC 61.2542

 

  • MktCap 3343394.0
  • FreeCF/Share -6.9266
  • PFCF -0.9222
  • PE -0.3845
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -8.6052

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
PTIX
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company's peptide-based drug candidates for stress-related and central-nervous-system disorders.

Read More
image for news Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher
PTIX
Published: May 19, 2025 by: Benzinga
Sentiment: Neutral

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday.

Read More
image for news Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher
Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders
PTIX
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY AND SANTA BARBARA, CA / ACCESS Newswire / May 19, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") and Phytanix Bio Inc. have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction (the "Combination"). The combined entity, to be called Phytanix, Inc., will bring together two pipelines focused on stress-related and CNS disorders, five preclinical assets and one clinical-stage asset.

Read More
image for news Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders

About Protagenic Therapeutics, Inc. (PTIX)

  • IPO Date 2021-04-27
  • Website https://www.protagenic.com
  • Industry Biotechnology
  • CEO Dr. Garo H. Armen Ph.D.
  • Employees 1
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.